Document Detail

The total ischemic burden European trial (TIBET): design, methodology, and management. The TIBET Study Group.
MedLine Citation:
PMID:  1520648     Owner:  NLM     Status:  MEDLINE    
TIBET is a European multicenter, double-blind parallel group trial with the main objective of investigating whether total ischemic burden has important prognostic implications in patients with stable angina on treatment. A secondary objective is to compare the antianginal and antiischemic effects of atenolol (50 mg bid), nifedipine (20-40 mg bid), and their combination using standardized exercise testing and Holter monitoring techniques. The main primary end points are cardiovascular morbidity and mortality. The secondary end points are time to onset of significant ischemia, angina on exercise stress testing, exercise capacity at onset of angina, 1-mm ST-segment depression and termination of exercise, total duration and number of significant ischemic episodes during 48 hours of Holter monitoring, and their circadian distribution. The target population, the assessments, and the management of the trial are described in detail.
Related Documents :
6363078 - Efficacy, duration and mechanism of action of nifedipine in stable exercise-induced ang...
7124628 - Effect of nifedipine on exercise-induced left ventricular dysfunction and myocardial hy...
6796288 - The effects of lidoflazine on exercise performance and thallium stress scintigraphy in ...
3930248 - The time of onset of action of sublingual nitroglycerin in exercise-induced angina pect...
19432298 - Effects of acute exercise on atherogenic lipids in untreated mild hypertensive patients.
8774818 - Benefits and limitations of rate adaptive pacing under laboratory and daily life condit...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy     Volume:  6     ISSN:  0920-3206     ISO Abbreviation:  Cardiovasc Drugs Ther     Publication Date:  1992 Aug 
Date Detail:
Created Date:  1992-10-09     Completed Date:  1992-10-09     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8712220     Medline TA:  Cardiovasc Drugs Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  379-86     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angina Pectoris / complications,  drug therapy*,  mortality
Atenolol / therapeutic use*
Coronary Disease / etiology*
Data Interpretation, Statistical
Double-Blind Method
Drug Therapy, Combination
Electrocardiography, Ambulatory
Exercise Test
Middle Aged
Nifedipine / therapeutic use*
Reg. No./Substance:
21829-25-4/Nifedipine; 29122-68-7/Atenolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Influence of the rt-PA dose (1 mg/kg versus 1.5 mg/kg) and duration of administration on the patency...
Next Document:  Intermittent infusion of dobutamine in the therapy of severe congestive heart failure--long-term eff...